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Abstract  
Saw-scaled vipers (genus Echis) are one of the leading causes of snakebite morbidity and 
mortality in parts of Sub-Saharan Africa, the Middle East, and vast regions of Asia, constituting a 
public health burden exceeding that of almost any other snake genus globally. Venom-induced 
consumption coagulopathy, owing to the action of potent procoagulant toxins, is one of the most 
relevant clinical manifestations of envenomings by Echis spp. Clinical experience and prior studies 
examining a limited range of venoms and eected antivenoms have demonstrated for some 
antivenoms an extreme lack of antivenom cross-reactivity between different species of this genus, 
sometimes resulting in catastrophic treatment failure. This study undertook the most comprehensive 
testing of Echis venom effects upon the coagulation of human plasma, and also the broadest 
examination of antivenom potency and cross-reactivity, to-date. 10 Echis species/populations and 
four antivenoms (two African, two Asian) were studied. The results indicate that the venoms are, in 
general, potently procoagulant but that the relative dependence on calcium or phospholipid co-
factors is highly variable. Additionally, three out of the four antivenoms tested demonstrated only a 
very narrow taxonomic range of effectiveness in preventing coagulopathy, with only the SAIMR 
antivenom displaying significant levels of cross-reactivity. These results were in conflict with 
previous studies using prolonged preincubation of antivenom with venom to suggest effective 
cross-reactivity levels for the ICP Echi-Tab antivenom. These findings both inform upon potential 
clinical effects of envenomation in humans and highlight the extreme limitations of available 
treatment. It is hoped that this will spur efforts into the development of antivenoms with more 
comprehensive coverage for bites not only from wild snakes but also from specimens widely kept in 
zoological collections. 
 
 
Introduction 
Envenoming and deaths resulting from snakebite represent an important public health 
concern, particularly throughout rural areas of South Asia and Sub-Saharan Africa in which access 
to sufficient medical facilities and antivenoms can be limited (Gutiérrez et al., 2006; Kasturiratne et 
al., 2008; Maduwage and Isbister, 2014). It is estimated that snakebite affects around 5 million 
people and accounts for more than 100,000 deaths annually (Chippaux, 1998; White, 2005; 
Kasturiratne et al., 2008). However these numbers are dramatic underestimations due to poor or 
entirely absent epidemiological data in many regions. Most severe cases of envenoming are 
attributed to species belonging to the Elapidae and Viperidae families (Gutiérrez et al., 2006). 
Typically, venoms from elapid snakes induce neuromuscular paralysis and are thus classed as 
neurotoxic, whereas viperid snake venoms most commonly target haemostasis (e.g., coagulation 
dysfunction, fibrinolysis, thrombosis) and induce local tissue damage, and are thus broadly 
categorised as cytotoxic and haemotoxic (Boyer et al. 2015; Markland, 1998; Sajevic et al., 2011; 
Warrell, 2010; White, 2005). Coagulopathy, which contributes to sustained bleeding and 
consequent haemodynamic disturbances (Warrell, 2010), is considered to be one of the most 
common serious systemic clinical pathologies induced by snake envenoming (Isbister, 2010). 
Accordingly, the Viperidae family contains some of the most medically significant snake genera 
worldwide (Gutiérrez et al., 2006; Warrell, 2010). Among them, saw-scaled or carpet vipers 
(Viperidae: Echis) are thought to be responsible for causing more snakebite deaths annually than 
any other genus (Warrell and Arnett, 1976).  
Currently, the genus Echis is thought to comprise at least nine species, distributed across four 
main clades: E. carinatus E. coloratus, E. ocellatus, and E. pyramidum (Pook et al., 2009; Alencar 
et al. 2016). They can be found across the semi-arid and seasonal climate regions of Sub-Saharan 
Africa north of the Equator, Arabia, Iran, Afghanistan and Uzbekistan, and in Pakistan, India and 
Sri Lanka, often in relative abundance. These areas are typically remote, rural, with absent or 
inadequate medical facilities, and with inhabitants of low socio-economic status. This, in 
conjunction with yielding highly toxic venom, renders Echis a common cause of injurious or fatal 
snakebite in the regions they occupy (Habib and Warrell, 2013). Though accurate statistics are 
sometimes difficult to ascertain due to poor documentation of bite cases in such developing nations, 
Echis ocellatus is responsible for as many as 95% of snake bites in northern Nigeria, for example 
(Meyer et al., 1997; WHO 2010a).  Victims are most commonly young males, a result of higher 
encounter rates arising from land cultivation or walking (Warrell and Arnett, 1976). In the absence 
of effective antivenom, case fatality rates following envenomation can be as high as 20% even with 
supportive medical treatment (Warrell and Arnett, 1976; Pugh and Warrell, 1980; Visser et al., 
2008), and those who survive are often left with permanent disability and disfiguring sequelae 
(Abubakar et al., 2010). Local effects of Echis viper envenoming typically include pain, swelling, 
blistering, and haemorrhage, which, in severe cases, can lead to necrosis and amputation. In such 
cases, the long-term socio-economic impact upon both bite victims and their families can be severe 
and is an often-overlooked consequence of snakebite (Vaiyapuri et al., 2013). 
In addition to localised effects, Echis toxins also induce dysfunctions of haemostasis, and 
mortality following envenomation is typically a result of systemic haemostatic disruption, which 
often leads to systemic haemorrhage (Warrell et al., 1977; Boyer et al. 2015). Of the three main 
processes involved in haemostasis (vasoconstriction, platelet plug formation and coagulation (Jin 
and Gopinath, 2016), the majority of snake venoms affecting haemostasis, including those of Echis, 
target the coagulation cascade. The coagulation cascade, whereby blood forms a clot following the 
stepwise activation of multiple clotting factors, requires the presence of Ca2+ ions and platelet-
phospholipids. These molecules act as co-factors to clotting proteins present in plasma, ultimately 
inducing the proteolytic cleavage of prothrombin to thrombin (Berny et al., 2010; Davie et al., 
1991; Jackson and Nemerson 1980; Munnix et al., 2007). Then, soluble fibrin monomers are 
formed by the cleavage of fibrinogen by the activated thrombin, and these monomers subsequently 
form an insoluble fibrin meshwork, resulting in a clot (Jin and Gopinath, 2016).  
The snake venom components responsible for perturbing haemostasis are variable, although 
the majority can be classified into four categories according to the part of the coagulation pathway 
upon which they act: factor V activators, factor X activators, prothrombin activators, and thrombin-
like enzymes (TLEs) or fibrinogenases (Lu et al., 2005; Kini and Koh, 2016; Slagboom et al. 2017). 
Within the genus Echis, the presence of prothrombin activators in species from each of the four 
main clades have been demonstrated (Gillissen et al., 1994; Mann, 1978; Mion et al., 2013; Porath 
et al., 1992; Warrell et al., 1977; Yamada et al., 1996). Prothrombin activators found within the 
genus are categorised into two subgroups according to their calcium dependence: ‘ecarin-like’ 
(Ca2+-independent) and ‘carinactivase-like’ activators (Ca2+-dependent), classified into groups A 
and B of snake venom prothrombin activators (Kini, 2005). Those belonging to the ‘ecarin-like’ 
group are named so following the discovery of a prothrombin activator (ecarin) with an 
unprecedented Ca2+-independent activity, isolated from Echis carinatus venom (Morita and 
Iwanaga, 1978). In contrast, ‘CA-like’ activators exhibit Ca2+-dependent activity, e.g., the 
prothrombin activator carinactivase, isolated from Echis leucogaster venom (Yamada et al., 1996). 
These toxins are responsible for the catalysis of prothrombin into thrombin. In natural prey items, 
this results in rapid subjugation through intravascular coagulation leading to cardiovascular 
collapse. However, in humans, the dilution of the venom into a much larger blood volume results in 
the formation of millions of microthrombi. In and of themselves, microthrombi are not lethal, but 
their formation consumes the majority of available essential clotting factors. Clinically, this leads to 
low or undetectable concentrations of fibrinogen (Isbister, 2010) and to multiple blood factor 
deficiencies, a potentially lethal condition known as venom-induced consumption coagulopathy 
(VICC) (Gillissen et al., 1994; Mann, 1978; Mion et al., 2013; Porath et al., 1992; Warrell et al., 
1977). Coagulopathy also contributes to the generation of additional systemic pathologies in human 
bite victims, including internal haemorrhage, such as cerebrovascular accident (Boyer et al. 2015; 
Warrell et al., 1977). 
Despite envenomation by all Echis species manifesting similar clinical symptoms, previous 
studies have documented considerable inter- and intraspecific variations in their venom composition 
(Barlow et al., 2009; Casewell et al., 2009, 2014; Schaeffer, 1987), apparently driven at least in part 
by natural selection for different diet spectra between the clades (Barlow et al., 2009; Richards et 
al., 2012, Savanur et al., 2014). This suggests that variation in the molecular mechanisms inducing 
these pathologies also exists. Such interspecific variation in toxin expression, and therefore in 
venom antigenicity, can greatly affect the ability of an antivenom to neutralise a given venom 
(Bénard-Valle et al. 2015; Fry et al., 2003; Harrison et al., 2003). Antivenoms consist of polyclonal 
antibodies purified from the serum or plasma of animals hyperimmunised with the target species’ 
venom (Bénard-Valle et al. 2015; Heard et al., 1999; Theakston and Warrell, 1991). Due to their 
polyclonal nature, antivenoms are able to neutralise multiple venom components (Gutiérrez et al., 
2003; Gutiérrez et al 2014); however, the antibodies are specific to the venoms from which they 
were developed (Bénard-Valle et al. 2015). Consequently, while antivenoms are typically marketed 
as a therapeutic treatment for envenomation by a given species, intraspecific venom variation can 
reduce antivenom efficacy, dependent upon the difference between the venom composition of the 
individuals which were used for antivenom manufacture and the individual which delivered the bite 
(Bénard-Valle et al. 2015; Boyer et al. 2015). It is well documented that the success rates achieved 
by different antivenoms in treating Echis snakebites can vary significantly depending on the 
geographical location of the bite due to regional variation of the species’ venom (Abubakar et al., 
2010; Calvete et al., 2016; Casewell et al., 2010), which can translate into catastrophic treatment 
failure and case fatality rates increased by an order of magnitude in a tropical clinical setting (Alirol 
et al. 2015; Visser et al., 2008; Warrell and Arnett, 1976; Warrell et al. 1980).  
In light of the complications associated with Echis envenomings, from a clinical perspective, 
there is a distinct need to characterise the coagulant activity of venoms of this genus, with particular 
reference to geographical variation, and to explore the implications this may have for antivenom 
cross-reactivity. In this study, a comparative analysis of the venoms of six representative species 
belonging to the four main clades of Echis was conducted. Coagulation assays were used to explore 
the interspecific and intraspecific variations of coagulopathic toxicity within Echis. Antivenom 
cross-reactivity was investigated by comparing the neutralising capacity of four Echis antivenoms. 
This research has been conducted to provide the first comprehensive reference framework for Echis 
venom coagulopathic effects and differential response to antivenoms.  
Materials and Methods 
Venom samples 
A total of ten Echis pooled-venom samples were included in this study, comprising six 
representative species belonging to the four main clades of the genus and from across its 
geographical distribution. The venoms were sourced from the cryogenic venom collection of the 
Venom Evolution Lab, University of Queensland and that of the Alistair Reid Venom Research 
Unit, Liverpool School of Tropical Medicine. Species and localities were as follows: E. carinatus 
(India), E. c. sochureki (Mithi, Tharparkar District, Sindh Province, Pakistan), E. c. sochureki 
(United Arab Emirates), E. coloratus (Saudi Arabia), E. jogeri (Bandafassi, Kédougou Region, 
Senegal), E. leucogaster (Mali), E. ocellatus (Ghana), E. ocellatus (Mali), E. ocellatus (Nigeria), 
and E. pyramidum leakeyi (Kenya). Pooled samples were used to account for any potential venom 
variation between individuals due to such variables as sex and age. Working stock solutions from 
freeze-dried venom were reconstituted to a concentration of 1mg/ml in 50% deionised water / 50% 
glycerol (Sigma-Aldrich) to prevent freezing and thus reduce enzyme degradation and preserve 
enzymatic activity. Working stocks were stored at -20°C and used for all subsequent analyses. 
 
Human plasma  
Human plasma was provided by the Australian Red Cross (44 Musk Street, Kelvin Grove, 
Queensland 4059). Three batches of pooled plasma (Lot#4456062 (Rhesus A+), Lot#4439715 
(Rhesus A-), Lot#4439719 (Rhesus O-)) were further pooled and aliquoted. The plasma aliquots 
were then flash frozen in liquid nitrogen and stored at -80°C until use. For all coagulation analyses, 
plasma aliquots were defrosted in an Artic refrigerated circulator SC150-A40 for 5 minutes (min) at 
37°C and immediately used for experimentation.  
 
Coagulation analyses  
Coagulation analyses were performed on a Stago STA-R Max® automated coagulation 
analyser (Stago, Asnières sur Seine, France) using Stago Analyser software v0.00.04 (Stago, 
Asnières sur Seine, France). To check the quality of the plasma, positive and negative controls were 
conducted and compared to pre-established plasma clotting parameters in the presence and absence 
of an activator (49-51 seconds (s) and 450-550 s respectively). The positive control was conducted 
by performing a standardised activated Partial Thromboplastin Time (aPTT) test (Stago Cat#T1203 
TriniCLOT APTT HS). 50 µL Kaolin (STA C.K.Prest standard kit, Stago Cat#00597), a 
coagulation activator, was added to 50 µL plasma and incubated for 120 seconds. 50 µL CaCl2 
(0.025 M, Stago Cat#00367) was then added, and time until clot formation was measured. As a 
negative control, test conditions in the absence of venom were replicated. 50 µL buffer solution (30 
µL 50% deionised H2O / 50% glycerol in 270 µL Owren-Koller (OK) buffer) was added to 50 µL 
CaCl2, 50 µL phospholipid and 25 µL OK buffer, and then incubated for 120 s at 37°C. 75 µL 
plasma was then added and clotting time measured. Both controls were run in triplicate before 
commencing any venom analyses.  
In order to determine clotting times effected by the addition of varying venom concentrations, 
venom working stock solution was diluted with Owren Koller (OK) Buffer (Stago Cat# 00360) as 
appropriate in order to perform 10-point dilution series (µg/ml: 20, 10, 5, 2.5, 1.33, 0.66, 0.4, 0.2, 
0.1, and 0.05). 50 µL of CaCl2 with 50 µL phospholipid (cephalin prepared from rabbit cerebral 
tissue from STA C.K Prest standard kit, Stago Cat# 00597, solubilised in OK Buffer) were added to 
50 µL of the diluted venom. An additional 25 µL of OK Buffer was added to the cuvette and 
incubated for 120 seconds at 37°C before adding 75 µL human plasma (total volume 250 µL 
/cuvette). Time until clot formation was then immediately monitored by the automated analyser. 
Tests were conducted in triplicate, with plasma and venom being replaced every 15-30 minutes to 
minimise enzyme degradation.  
 
Phospholipid and calcium dependence  
In order to test for co-factor dependence of the venoms, the aforementioned coagulation 
analyses were run both with and without CaCl2 and/or phospholipid. The experimental protocol was 
identical, with the exception that 50 µL OK Buffer was added as a substitute for the removed co-
factor to ensure consistency in final test volumes (250 µL). Tests were conducted in triplicate, with 
plasma and venom being replaced every 15-30 minutes to minimise enzyme degradation.  
 
Antivenom tests 
The relative efficacy of four polyvalent and monovalent antivenoms were investigated in this 
study. The previously measured whole plasma clotting times for each venom were used as a guide 
for antivenoms effects. Four antivenoms were assessed; three polyvalent: (a) EchiTAb-Plus-ICP, 
from Instituto Clodomiro Picado, Costa Rica (Lot 5620715PALQ), (b) Sii Polyvalent Anti-snake 
Venom Serum from Serum Institute Of India LTD, India (Lot 045D0004), and (c) Snake Venom 
Antiserum I.P. from VINS Bioproducts LTD, India (Lot 1081); and one monovalent: SAIMR Echis 
antivenom provided by South African Vaccine Producers (SAVP) (South Africa – Lot 2147)  
(Table 1). 
Antivenoms which were provided in lyophilised form were reconstituted in sterile water (if 
indicated by the manufacturer), aliquoted, and stored at 4°C. In order to ascertain the potency, as 
each antivenom vial contained the same final volume (10ml) equal volumes of each antivenom 
were used for testing. For antivenom testing, all test conditions replicated that of the coagulation 
analyses, with the exception that 25µl of antivenom working solution (50 µL reconstituted 
antivenom in 950 µL OK buffer) used in place of 25µl of OK Buffer: 50 µL venom, 50 µL calcium, 
50 µL phospholipid, 25 µL antivenom, 120 s incubation time, 75 µL plasma. Time until clot 
formation was then immediately measured. Experiments were conducted in triplicate, with plasma 
and venom being replaced every 15-30 minutes to minimise enzyme degradation.  
 
Statistical analysis 
Coagulation times (seconds) for each of the venoms and antivenoms were graphed using Prism 7.0 
software (GraphPad Software Inc, La Jolla, CA, USA) to produce concentration response curves. 
Calculation of EC50 (concentration of venom at which 50% of the effect is observed) values for the 
venom and antivenom concentration curves for each dataset were performed using Prism 7.0 
software (GraphPad Software Inc, La Jolla, CA, USA). Data is expressed as mean ± SD. After 
EC50s were calculated, the relative antivenom efficacy was calculated using the formula: 
x=abc/def-1 with a= antivenom EC50 x-axis, b= antivenom EC50 y-axis, c= antivenom starting 
clotting time, d= venom EC50 x-axis, e= venom EC50 y-axis and  f= venom starting clotting time. 
 
The phylogenetic tree used was based upon a previously published species tree (Pook et al., 2009; 
Alencar et al. 2016) and created using Mesquite software (version 3.2), which was then imported 
into Rstudio using the APE package (Paradis et al., 2004). Ancestral states were estimated for all 
traits (including the proportional shift of the relative co-factor dependence and relative antivenom 
efficacy) using maximum likelihood as implemented in the contMap function of the R package 
phytools (Revell, 2012). We then fit pGLS models (Symonds and Blomberg, 2014) in caper (Orme 
et al., 2015) to test for relationships. Specific scripts for each step in R are as follows: 
 
PHYTOOLS CODE 
>library(ape) 
>library(maps) 
>library(phytools) 
> # senci.contMap is a slight modification of errorbar.contMap that trims 95% CIs of ancestral state reconstructions to a 
sensible range, e.g. for traits bound between 0 and 1 
# Example of code for implementing it would be as follows (lines separated by semicolons): pasr<-
contMap(tree,mapdat,plot=F,lims=c(0,1)) ; plot(setMap(pasr,invert=T)) ; 
senci.contMap(setMap(pasr,invert=T),mini=0,maxi=1) 
senci.contMap<-function(obj,...){ 
if (hasArg(x))  
        x <- list(...)$x 
    else x <- setNames(sapply(1:Ntip(obj$tree), function(x, obj) { 
        ii <- which(obj$tree$edge[, 2] == x) 
        ss <- names(obj$tree$maps[[ii]][length(obj$tree$maps[[ii]])]) 
        obj$lims[1] + as.numeric(ss)/(length(obj$cols) - 1) *  
            diff(obj$lims) 
    }, obj = obj), obj$tree$tip.label) 
    if (hasArg(scale.by.ci))  
        scale.by.ci <- list(...)$scale.by.ci 
    else scale.by.ci <- TRUE 
    if (hasArg(lwd))  
        lwd <- list(...)$lwd 
    else lwd <- 14 
    tree <- obj$tree 
    aa <- fastAnc(tree, x, CI = TRUE) 
if (hasArg(min))#added lines here 
for (i in 1:length(aa$CI95[,1])){ #added lines here 
    aa$CI95[i,1]<-ifelse(aa$CI95[i,1]<list(...)$min,list(...)$min,aa$CI95[i,1]) #added lines here 
    } #added lines here 
else aa$CI95[,1]<-aa$CI95[,1] #added lines here 
if (hasArg(max)) #added lines here 
for (i in 1:length(aa$CI95[,2])){ #added lines here 
    aa$CI95[i,2]<-ifelse(aa$CI95[i,2]>list(...)$max,list(...)$max,aa$CI95[i,2]) # added lines here 
    } #added lines here 
else aa$CI95[,2]<-aa$CI95[,2] #added lines here 
    xlim <- range(aa$CI95) 
    if (xlim[2] > obj$lims[2] || xlim[1] < obj$lims[1]) { 
        cat(paste("  -----\n  The range of the contMap object, presently (",  
            round(obj$lims[1], 4), ",", round(obj$lims[2], 4),  
            "), should be equal to\n  or greater than the range of the CIs on ancestral states: (",  
            round(xlim[1], 4), ",", round(xlim[2], 4), ").\n",  
            sep = "")) 
        cat(paste("  To ensure that your error bars are correctly plotted, please recompute your\n",  
            "  contMap object and increase lims.\n  -----\n",  
            sep = "")) 
    } 
    d <- diff(obj$lims) 
    if (scale.by.ci) { 
        v <- aa$CI95[, 2] - aa$CI95[, 1] 
        v <- v/max(v) 
    } 
    else v <- rep(0.5, tree$Nnode) 
    n <- length(obj$cols) - 1 
    lastPP <- get("last_plot.phylo", envir = .PlotPhyloEnv) 
    h <- max(nodeHeights(tree)) 
    for (i in 1:tree$Nnode) { 
        ii <- round((aa$CI95[i, 1] - obj$lims[1])/d * n) 
        jj <- round((aa$CI95[i, 2] - obj$lims[1])/d * (n + 1)) 
        cols <- obj$cols[ii:jj] 
        add.color.bar(leg = 0.1 * h * v[i], cols = cols, prompt = FALSE,  
            x = lastPP$xx[i + Ntip(tree)] - 0.05 * h * v[i],  
            y = lastPP$yy[i + Ntip(tree)], title = "", subtitle = "",  
            lims = NULL, lwd = lwd) 
    } 
} 
>data<-read.csv(file.choose())  
>dat<-data 
>mapvar<-dat$var 
>names(mapvar)<-dat$species 
>tree<-read.tree(file.choose())  
>tree<-chronos(tree) 
>asr<-contMap(tree,mapvar,plot=F) 
 
For red (warmer) zone for the higher numbers (eg antivenom shifts) the below was used.  
>plot(setMap(asr,col=c(1,4,5,3,7,2,6,8))) 
>senci.contMap(setMap(asr,col=c(1,4,5,3,7,2,6,8)),min=x,max=y) 
 
For red (warmer) zone for smaller numbers (eg clotting time and co factors) the below was used 
>plot(setMap(asr,col=c(8,6,2,7,3,5,4,1)),lwd=10) 
>senci.contMap(setMap(asr,col=c(8,6,2,7,3,5,4,1)),min=x,max=y) 
 
In both cases, the x and y for senci were the low and high numbers (respectively) for the particular dataset. 
 
PHYLOGENETIC GENERALISED LEAST SQUARES REGRESSION (PGLS) STEP 
>library(caper)  
>data<-read.csv(file.choose())  
>tree<-read.tree(file.choose())  
>com<-comparative.data(tree,data,species)  
 
For values of variable range in the responder column, these steps were used 
>mod<-pgls(var1~var2,com,lambda="ML")  
>summary(mod) 
 
For 0 to 1 values in the responder column 
>mod<-pgls(57.295*asin(sqrt(var1))~var2,com,lambda="ML") 
>summary(mod) 
 
Results and Discussion 
Procoagulant activity was revealed to be a dynamic feature without a strong phylogenetic 
pattern, and also without any obvious relationship with the diet spectra of the clades, despite diet-
specific differences in venom lethality to prey (Barlow et al., 2009), therefore suggesting this is a 
dynamic ancestral functional phenotype in Echis spp. Testing revealed all venoms to follow a 
similar dilution curve trajectory. However, clotting times at maximal venom concentration (20 
µg/mL) varied from 19.53+/-1.30s for E. pyramidum leakeyi to 40.13+/-1.20s for E. carinatus 
(India), though most venoms induced a clot in around 20-25 seconds (Figure 1, Table 2). Only E. 
carinatus (India) and E. leucogaster (Mali) venoms took longer than 30 s to generate a clot (Figure 
1). There was significant variation in clotting time within each of the three major clades. E. 
carinatus (India) was significantly slower than the two other venoms in the E. carinatus clade (E. c. 
sochureki (Pakistan) and E. c. sochureki  (UAE), but with E. c. sochureki (Pakistan) and E. c. 
sochureki (UAE) not differing significantly from each other. E. leucogaster was also significantly 
slower than its closest relatives in this study (E. coloratus and E. pyramidum leakeyi), with E. 
coloratus and E. pyramidum leakeyi also being significantly different in their clotting times relative 
to each other. Within the E. jogeri/E. ocellatus clade all venoms differed significantly from each 
other, with coagulant activity for the four venoms ranging from 19.63s (E. jogeri (Senegal)) to 
27.0s (E. ocellatus (Ghana)). 
The interspecific variation in calcium cofactor dependence showed a strong phylogenetic 
pattern and varied from the almost independent E. carinatus (India locale), with a clotting time shift 
of only 0.42 +/- 0.02-fold in the absence of calcium, to total dependence in E. coloratus (Saudi 
Arabia), which was unable to induce a clot in the instrument’s maximum measurement time range 
(999 s) and thus has a clotting time shift of at least 17.5-fold (Figure 2, Table 2). The basally split 
E. carinatus clade ranged from strong to moderate calcium independence. The E. jogeri/E. ocellatus 
clade displayed consistent strong calcium-independence. In contrast, all venoms from the E. 
pyramidum clade exhibited a high degree of calcium dependence. Taken in the context of the 
phylogeny (Figure 2) this suggests that low levels of calcium dependence is the plesiotypic 
condition of the Echis genus.   
In contrast to the extreme effect seen with regard to calcium cofactor dependence, relative 
shifts in clotting time in the absence of additional phospholipid cofactor were substantially less than 
those of calcium, and also lacked the strong phylogenetic pattern evident for calcium dependence 
(Figure 2, Table 2). Relative phospholipid dependence ranged from 0.04 +/- 0.01-fold for E. 
carinatus (India) through to 0.90 +/- 0.07-fold for E. c. sochureki (Pakistan). The third member of 
this clade, E. sochureki (UAE locale; 0.48 +/- 0.03-fold) demonstrated intermediate dependence. 
The other clades were also variable. Thus, while phospholipid dependence in general was less 
pronounced, the lack of phylogenetic consistency suggests that it is a labile character relative to that 
of calcium dependence.  
A higher relative degree of calcium dependence predicted increased relative phospholipid 
dependence (PGLS: t=2.2734, p=0.03851), but the reverse was not true in that the relative degree of 
phospholipid dependence did not predict that of calcium dependence (PGLS: t=1.6467, p=0.13824). 
This may suggest that changes in calcium dependence subsequently lead to changes in phospholipid 
dependence, but this directional suggestion remains tentative. Higher relative degree of 
phospholipid dependence was associated with faster clotting times, though this effect was 
marginally non-significant (PGLS: t=-2.1562, p=0.063160) (Figure 3). In contrast, the relative 
calcium dependence did not predict clotting time (PGLS: t=-1.7817, p=0.11266). Thus there 
appears to be a positive correlation between the ability of the enzymes to use phospholipid and their 
ability activate prothrombin, which is consistent with neofunctionalisation of these enzymes for 
such an activity relative to their ancestral protease activity. Thus the more the enzymes are able to 
utilize phospholipid for the newly evolved prothrombin activation activity, the faster the reaction 
proceeds. The structural features responsible for this phospholipid utilisation are unknown and thus 
represent a rich area of future research. The dynamic nature of this in relationship to the phylogeny 
of the snakes themselves is a particularly fascinating riddle (Figure 2). Additional studies are 
required however to confirm this directionality and the biochemical mechanisms behind it. 
The four antivenoms tested using equal volumes of each antivenom had extremely variable 
results both in potency and species targeted (Figures 4-7, Tables 3 and 4). EchiTAb-Plus-ICP 
antivenom had the strongest effect of all the antivenoms tested in this study, being for example 
twice as effective as SII in relation each antivenom’s best neutralised venom but not to the 6.6-fold 
ratio that may be anticipated from the package insert details (Table 1). Consistent with E. ocellatus 
venom being used in the immunising mixture, this antivenom demonstrated strong selectivity for 
the West African species E. ocellatus venoms and, to a lesser extent, the E. jogeri venom. The 
strongest effect was seen for E. ocellatus (Ghana) venom which had the clotting curve 
proportionally shifted with an effect of 65-fold. The other E. ocellatus populations were also well 
neutralised, but to a lesser extent. Unexpectedly, of the E. ocellatus samples tested, the population 
from Nigeria was the least affected by the EchiTab-ICP, despite the antivenom being manufactured 
from pooled venoms of E. ocellatus collected from Nigeria (Gutiérrez et al., 2005). While the 
precise locality of the Nigerian sample used in this study was not known, the results never-the-less 
indicative of geographical or individual variation within the region and follow-up studies should 
investigate this matter further. The antivenom also significantly shifted the clotting curve of E. 
jogeri. However, despite showing good efficacy for this clade, the EchiTab-ICP had little effect 
upon the other venoms thus demonstrating a narrow taxonomic range of efficiency.  
In discordance with these findings (Figures 4-7, Tables 3 and 4), a previous study described 
the ability of the ICP antivenom to neutralise coagulant activity of the venoms of E. pyramidum and 
E. leucogaster (Segura et al., 2010). This discrepancy is likely to be attributable to differences in 
experimental protocol. Segura et al. (2010) used a more prolonged incubation time (30 minutes 
incubation) as compared to the protocol used in the present study (2 minutes incubation). Longer 
incubation times would likely conceal differences in efficacy between venom/antivenom pairs as 
slower, weaker binding combinations would have time to reach the levels more quickly obtained by 
faster, stronger binding combinations. The traditional protocols to assess the neutralizing ability of 
antivenoms at the preclinical level involve the incubation of venom and antivenom for 30 min or 
even for one hour before testing [see for example Christensen 1955, Bolaños 1977, and WHO 
1981]. Moreover, the 30 min incubation protocol at 37 °C is indicated in the current version of the 
official WHO guidelines for antivenom production and quality control (WHO, 2010).  In contrast, 
the new protocol used in this study introduces a more rigorous evaluation of the neutralizing 
capacity of antivenoms by reducing the incubation time to 2 min, thus demanding high affinity 
antibodies for the neutralization while also ascertaining the ability of the antivenoms to neutralise 
the coagulopathic enzymatic activity. 
Consistent with E. pyramidum (Ethiopia/Eritrea) and E. ocellatus (Nigeria) venoms being 
used in the immunising mixture, the SAIMR antivenom had the strongest selectivity for the species 
within the E. pyramidum clade but also displayed significant cross-reactivity for E. ocellatus 
venoms as well as the E. jogeri venom from the same clade (Figures 4-7, Tables 3 and 4). Thus our 
results confirm that the SAIMR antivenom is effective against both East and West African Echis 
species and while it may require more antivenom for the treatment of West African species it 
clearly has the broadest coverage of African Echis species (Figures 4-7).  
Neither Indian antivenom was able to neutralise the Indian-locale venom samples included in 
this study (Figures 4-7, Tables 3 and 4). While both antivenoms use the Chennai population of E. 
carinatus in the immunising mixture, the geographical locality within India for the venom used in 
this study is unknown. However, this clearly points to potential intra-country clinical issues and this 
disparity should be the focus of an urgent follow-up study as this country is notable for such 
variation (Kochar et al. 2007). The SII antivenom performed well against the Pakistan E. c. 
sochureki population and to a lesser but still significant extent, the UAE E. c. sochureki population. 
Despite having a package insert stated potency equivalent to that of SII (Table 1), the VINS 
antivenom performed comparatively poorly with values comparable with the low-level cross-
reactivity of EchiTAb-Plus-ICP and SAIMR for the Pakistan and UAE E. c. sochureki populations. 
Both the SII and VINS antivenoms give the same stated neutralising ability against the lethal effect 
of venoms when tested through the historical method of 30 min preincubation of antivenom with 
venom and then injection of the mixture into mice (Table 1). However, their performance was 
markedly different in this study regarding ability to neutralize the coagulant activity (Tables 3 and 
4). Thus the VINS antivenom can be predicted to have little or no likely clinical usefulness against 
the South Asian or African venoms tested in this study without requiring extremely large doses 
relative to the other antivenoms studied. These findings agree with a previous study showing that 
VINS antivenom is highly inefficient in the neutralisation of E. ocellatus from Cameroon (Calvete 
et al., 2016). 
Our findings demonstrate that there is gradated calcium dependence throughout the genus 
(Figure 2). This presents an intriguing example of venom variability and one with profound clinical 
implications. As the procoagulant activity of Echis spp. venoms is driven by prothrombin activating 
SVMPs, the calcium dependency (Figure 2) may shed light on the type of predominant type in each. 
Prothrombin activating SVMP are divided into Class A (calcium independent) and Class B (calcium 
dependent) (Casewell et al. 2015; Kini and Koh, 2016). These functional/structural divisions are 
sometimes referred to as ecarin-like or carinativase-like based upon the first of each type described 
for each. These functional classes are also reflective of structural differences, with the monomeric 
P-IIIa SVMP making up Class A while Class B is a P-IIIa SVMP non-covalently linked to a lectin 
dimer (with the two lectin subunits covalently linked to each other) (Yamada et al. 1996; Casewell 
et al. 2015). This trimer differs from the classical P-IIId SVMP which are covalently linked to a 
lectin dimer (Casewell et al. 2015). As low levels of calcium dependence is the plesiotypic state 
(Figure 2), this suggests that the evolution of a monomeric calcium independent P-IIIa SVMP 
preceded the evolution of the apotypic trimeric calcium dependent P-III. The reasons for the 
requirement for calcium due to the structural derivation in the P-III SVMPs remains to be 
elucidated and highlights an area for future research. However, due to the structural differences in 
the two functional classes, the venoms used in the antivenom immunising mixture may bias the 
antivenom efficacy towards dependent or independent venom types and thus may be responsible in 
part for the extreme clade-specific antivenom effects in combination with diversification of the 
physico-chemical properties of the prothrombin activating SVMP toxins responsible for the lethal 
effects.  
This study has demonstrated that the antivenoms were highly variable not only in comparative 
potency in neutralising procoagulant activity, but also in relative species selectivity (Figures 4-7, 
Tables 3 and 4). The most potent antivenom (EchiTAb-Plus-ICP) also displayed the extremely 
narrow species selectivity. Although procoagulant activity is not the sole mode of action of Echis 
venoms it does play a key role in lethality. Our results indicate that the different Echis antivenoms 
tested are of greatest usefulness for neutralisation of this activity within the clade of venoms from 
which the immunising venom was drawn, with limited regional cross-reactivity. This suggests that, 
in at least the case of Echis, phylogenetic affinities can be used as a roadmap for the selection of 
antivenoms to test for effectiveness for unstudied populations, and, in an emergency, for the 
treatment of bites by captive specimens, although other factors may also play a role (e.g., Gillissen 
et al., 1994). This underscores the importance of phylogenetic and systematic studies as a guide for 
antivenom design and testing in this genus (Fry et al., 2003; Williams et al., 2011).    
The results of this study demonstrating very narrow taxonomic efficacy ranges (Figure 7) are 
in conflict with previous studies, which suggested much broader efficacy ranges but involved much 
longer (15x) incubation times of antivenom-venom mixtures and a protocol that selected for ability 
to impede lethality rather than directly measuring impedence of lethality  (Warrell et al. 1980; 
Casewell et al., 2010; Segura et al. 2010). Future work should be undertaken to investigate whether 
the prolonged venom:antivenom pre-incubation times used as standard in preclinical testing (WHO, 
2010b) are actually predictive of clinical efficacy. Venom binding by the antivenom under such 
idealised circumstances may not necessarily reflect what occurs in a clinical setting. Venom and 
antivenom interactions in the body are due to opportunistic encounters in a dynamic system. Thus 
the longer incubation times historically used in preclinical testing would allow time for low-affinity 
antibodies to bind as they are in forced proximity with the venom for biologically unrealistic period 
of time. Conversely the shorter incubation times used in this study may in fact better reflect the 
real-world opportunity for venom binding by the high affinity antibodies in the antivenom. Such 
considerations will however require rigorous future studies to resolve these important questions. 
In conclusion, this study has revealed extreme cross-reactivity issues for Echis antivenoms 
(Figures 4-7) and highlights the urgent need for the development of cost-effective, pan-regional 
antivenoms for Africa and Asia that cover all the Echis venom clades in their corresponding 
continents. Moreover, the Mid-East region and Arabian Peninsula contain species from three of the 
four Echis clades, including the south Asian carinatus group (E. carinatus sochureki), the Arabian 
coloratus group (E. coloratus, E. omanensis) and the African pyramidum clade (E. borkini, E. 
khosatzkii). Consequently, there is a clear need to test antivenoms used in the region for efficacy 
against all relevant venoms using the biologically relevant incubation times in the protocol of this 
study. Further, there may be also a need for a combined African/Asian Echis antivenom. It is hoped 
that these results will stimulate such life-saving efforts. The results of our study are of particular 
immediate concern as some manufacturers are selling their products outside the region from which 
the immunising venom was obtained and this unscrupulous marketing of non-regional specific 
antivenoms has resulted, in some cases, in an over twenty-fold increase in fatality rate (Alirol et al. 
2015; Visser et al., 2008; Warrell 2008). 
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Table 1: Antivenoms studied 
Antivenom 
 
Stated species coverage. Stated neutralising 
capacity (per mL 
antivenom) 
EchiTAb-Plus-ICP, Instituto 
Clodomiro Picado, Costa 
Rica; Lot 5620715PALQ.  
Equine whole IgG; specific Echis 
ocellatus, Bitis arietans and Naja 
nigricollis (Nigerian locality) 
No less than 3.0 mg E. 
ocellatus venom 
Sii Polyvalent Anti-snake 
Venom Serum, Serum 
Institute Of India LTD, 
India; Lot 045D0004. 
Equine F(ab’)2; specific Echis 
carinatus, Daboia russelli, Naja naja 
and Bungarus caeruleus. 
No less than 0.45 mg of E. 
carinatus venom 
Snake Venom Antiserum 
I.P., VINS Bioproducts 
LTD, India; Lot 1081. 
Equine F(ab’)2; specific Echis 
carinatus, Daboia russelli, Naja naja 
and Bungarus caeruleus. 
No less than 0.45 mg of E. 
carinatus venom 
SAIMR Echis pyramidum 
leakeyi antivenom, South 
African Vaccine Producers 
(SAVP), South Africa; Lot 
NO2147. Note the insert 
says E. carinatus but this is 
reflective of outdated 
taxonomy. Immunising 
venom mixture has been a 
combination Echis 
pyramidum specimens from 
Ethiopia/Eritrea and E. 
ocellatus from Nigeria 
(Priscilla Fleisher, SVAP 
personal communication) 
Equine F(ab’)2; specific Echis 
carinatus, paraspecific Echis 
coloratus 
Not stated 
 
  
Table 2: clotting times and co-factor influence 
Species 
20µg/ml clotting 
time (seconds) 
Calcium 
dependence* 
Phospholipid 
dependence* 
Echis carinatus carinatus (India) 40.13+/-1.20 0.42+/-0.02 0.04+/-0.01 
Echis carinatus sochureki (Pakistan) 20.83+/-0.77 4.07+/-0.01 0.90+/-0.07 
Echis carinatus sochureki (UAE) 21.60+/-0.96 3.4+/-0.04 0.48+/-0.03 
Echis coloratus (Saudi Arabia) 26.86+/-0.15 >17.5 0.70+/-0.19 
Echis jogeri (Senegal) 19.63+/-0.32 1.05+/-0.01 0.32+/-0.08 
Echis leucogaster (Mali) 38.77+/-1.8 9.67+/-0.04 0.29+/-0.05 
Echis ocellatus (Ghana) 27.90+/-1.30 1.01+/-0.01 0.33+/-0.02 
Echis ocellatus (Mali) 22.83+/-1.79 0.80+/-0.04 0.17+/-0.05 
Echis ocellatus (Nigeria) 24.67+/-1.36 1.18+/-0.07 0.44+/-0.03 
Echis pyramidum leakeyi (Kenya) 19.53+/-1.30 7.73+/-0.36 0.63+/-0.07 
 
*Co-factor dependence is the proportional shift in 20µg/ml clotting time without the presence of the 
co-facor.   
Table 3: Relative potency for each antivenom. Values indicate x–fold shift in clotting curves 
Species ICP SAIMR SII VINS 
Echis carinatus carinatus (India) 0.34+/-0.01 0.91+/-0.02 1.36+/-0.041 0.42+/-0.04 
Echis carinatus sochureki (Pakistan) 6.97+/-0.17 9.09+/-0.29 29.91+/-0.19 8.74+/-0.28 
Echis carinatus sochureki (UAE) 3.71+/-0.04 6.57+/-0.22 16.08+/-1.10 4.67+/-0.21 
Echis coloratus (Saudi Arabia) 1.39+/-0.29 21.75+/-2.61 2.21+/-0.21 1.21+/-0.42 
Echis jogeri (Senegal) 25.95+/-0.13 7.52+/-0.03 3.35+/-0.01 1.85+/-0.01 
Echis leucogaster (Mali) 2.07+/-0.55 22.58+/-0.40 1.55+/-0.24 0.35+/-0.01 
Echis ocellatus (Ghana) 64.40+/-1.16 14.35+/-0.50 0.75+/-0.05 0.50+/-0.07 
Echis ocellatus (Mali) 44.48+/-1.34 11.27+/-0.081 0.52+/-0.04 0.52+/-0.11 
Echis ocellatus (Nigeria) 34.28+/-0.56 14.40+/-0.26 2.13+/-0.08 1.71+/-0.66 
Echis pyramidum leakeyi (Kenya) 1.04+/-0.11 21.54+/-0.57 7.16+/-0.50 2.38+/-0.08 
 
  
Table 4: Pairwise comparison in antivenom efficacy*. 
Antivenom pairs Eca-I Ecs-P Ecs-U Eco-S Ejo-S 
ICP vs. SAIMR <0.0001 <0.0001 0.0012 <0.0001 <0.0001 
ICP vs. SII <0.0001 <0.0001 <0.0001 0.8708 <0.0001 
ICP vs. VINS 0.0169 <0.0001 0.24 0.9983 <0.0001 
SAIMR vs. SII <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
SAIMR vs. VINS <0.0001 0.3637 0.0151 <0.0001 <0.0001 
SII vs. VINS <0.0001 <0.0001 <0.0001 0.7943 <0.0001 
 Antivenom pairs Ele-M Eoc-G Eoc-M Eoc-N Epl-K 
ICP vs. SAIMR <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
ICP vs. SII 0.3659 <0.0001 <0.0001 <0.0001 <0.0001 
ICP vs. VINS 0.0017 <0.0001 <0.0001 <0.0001 0.0112 
SAIMR vs. SII <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
SAIMR vs. VINS <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
SII vs. VINS 0.0146 0.9594 >0.9999 0.3898 <0.0001 
* p-values from Tukey's multiple comparisons test 
Eca-I = E. carinatus (India), Ecs-P = E. c. sochureki (Pakistan), Ecs-U = E. c. sochureki (UAE), 
Eco-S = E. coloratus (Saudi Arabia), Ejo-S = E.jogeri (Senegal), Ele-M = E. leucogaster (Mali), 
Eoc-G = E. ocellatus (Ghana), Eoc-M = E. ocellatus (Mali), Eoc-N = E. ocellatus (Nigeria), Epl-K 
= E. pyramidum leakeyi (Kenya).  
 
  
 
Figure 1: A) Venom dose-response curves with values of means from N=3 with error bars 
indicating standard deviation (error bars at most concentrations are smaller than the symbols), and 
B). Ancestral state reconstruction of clotting times, where warmer colours represent faster clotting 
times. Bars indicate 95% confidence intervals for the estimate at each node. Note that due to the 
high dynamicity of venom evolution the ranges quickly become broad as one moves down the tree. 
Numbers at tips are means of N=3 maximum clotting times from (A) (Table 2). Phylogenetic tree is 
based upon (Pook et al., 2009; Alencar et al. 2016). 
  
Figure 2: Ancestral state reconstruction of relative co-factor dependence, where warmer colours 
represent greater cofactor dependence. Bars indicate 95% confidence intervals for the estimate at 
each node. Note that due to the high dynamicity of venom evolution the ranges quickly become 
broad as one moves down the tree. Numbers at tips are means from N=3 tests for x-fold shift in 
clotting time (Table 2). Phylogenetic tree is based upon (Pook et al., 2009; Alencar et al. 2016). 
 
  
Figure 3: Ancestral state reconstructions to show the inverse relationship between procoagulant 
activity (where warmer colours represent faster clotting times) and phospholipid cofactor 
dependence (where warmer colours indicate greater degree of dependence). Bars indicate 95% 
confidence intervals for the estimate at each node. Note that due to the high dynamicity of venom 
evolution the ranges quickly become broad as one moves down the tree. Numbers at tips are means 
from N=3 tests for x-fold shift in clotting time and phospholipid dependence (Table 2). 
Phylogenetic tree is based upon (Pook et al., 2009; Alencar et al. 2016). 
  
 Figure 4: Coagulation dose-response curves. Blue lines represent venom in optimal conditions (i.e. 
with calcium and phospholipid) while red line represents the clotting activity remaining after 2 
minute preincubation of venom with antivenom and then the same dilution series were run as for 
the blue line protocol. The antivenom remained a constant in the second protocol while the venom 
was diluted against it as per the X-axis concentrations (µg/ml). The y-axis is time (seconds). Values 
are means from N=3 with error bars indicating standard deviation. Eca-I = E. carinatus (India), Ecs-
P = E. c. sochureki (Pakistan), Ecs-U = E. c. sochureki (UAE), Eco-S = E. coloratus (Saudi 
Arabia), Ejo-S = E.jogeri (Senegal), Ele-M = E. leucogaster (Mali), Eoc-G = E. ocellatus (Ghana), 
Eoc-M = E. ocellatus (Mali), Eoc-N = E. ocellatus (Nigeria), Epl-K = E. pyramidum leakeyi 
(Kenya).  
 
Figure 5: Normalised logarithmic transformed views of clotting effects. Blue lines represent venom 
in optimal conditions (i.e. with calcium and phospholipid) while red line represents the clotting 
activity remaining after 2 minute preincubation of venom with antivenom and then the same 
dilution series were run as for the blue line protocol. The antivenom remained a constant in the 
second protocol while the venom was diluted against it. Values are means from N=3 with error bars 
indicating standard deviation. Eca-I = E. carinatus (India), Ecs-P = E. c. sochureki (Pakistan), Ecs-
U = E. c. sochureki (UAE), Eco-S = E. coloratus (Saudi Arabia), Ejo-S = E.jogeri (Senegal), Ele-M 
= E. leucogaster (Mali), Eoc-G = E. ocellatus (Ghana), Eoc-M = E. ocellatus (Mali), Eoc-N = E. 
ocellatus (Nigeria), Epl-K = E. pyramidum leakeyi (Kenya).  
  
 Figure 6: Comparison of the performance of each antivenom against a particular species. Equal 
volumes from each of the antivenoms was used as they all were of the same 10ml vial size. Thus 
the potency is relative to a consistent amount of antivenom used by volume not by stated protein 
content or efficacy claims. The data are thus direct head to head comparisons in this regard. Values 
are means of the ability to proportionally shift a curve, with the highest effect being ICP against 
Ghana which shifted the venom cuve of E. occelatus nearly sixty five times over (N=3 with error 
bars indicating standard deviation). Eca-I = E. carinatus (India), Ecs-P = E. c. sochureki (Pakistan), 
Ecs-U = E. c. sochureki (UAE), Eco-S = E. coloratus (Saudi Arabia), Ejo-S = E.jogeri (Senegal), 
Ele-M = E. leucogaster (Mali), Eoc-G = E. ocellatus (Ghana), Eoc-M = E. ocellatus (Mali), Eoc-N 
= E. ocellatus (Nigeria), Epl-K = E. pyramidum leakeyi (Kenya). 
  
 Figure 7: Ancestral state reconstruction of relative species selectivity for each antivenom where 
warmer colours represent better antivenom cross-reactivity.  Values are normalised N=3 means 
within an antivenom. Bars indicate 95% confidence intervals for the estimate at each node. Note 
that due to the high dynamicity of venom evolution the ranges quickly become broad as one moves 
down the tree. Phylogenetic tree is based upon (Pook et al., 2009; Alencar et al. 2016). 
